QLL.BO · BSE
Qualitek Labs Limited
₹646.4
+4.80% (+₹29.6)
Prev. close
₹616.8
Volume
1,32,800
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Qualitek Labs Limited
Qualitek Labs Limited offers technical testing and analysis services in India and internationally. The company offers inspection, certification, homologation, research and development, training programs, audit, and consultancy services. It serves automobiles, defence, electronics and electricals, pharmaceuticals, medical devices, metals, minerals, environment monitoring, food, and water industries. The company was incorporated in 2018 and is based in Noida, India. Qualitek Labs Limited is a subsidiary of TIC Services Private Limited.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Kamal Grover
Headquarters
Noida
Employees
677
Website
qualiteklab.comExchange
View on BSE ↗Key stats
Market cap
₹754.59 Cr
P/E ratio (TTM)
51.8
EPS (TTM)
₹12.51
Beta (1Y · daily vs NIFTY 50)
1.32
Shares float
41.19 L
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹19.14 Cr | ₹29.18 Cr | ₹70.23 Cr | ₹124.52 Cr | |
| EBITDA | — | ₹5.48 Cr | ₹8.13 Cr | ₹16.76 Cr | ₹29.81 Cr |
| — | ₹2.94 Cr | ₹4.31 Cr | ₹6.30 Cr | ₹13.62 Cr | |
| Diluted EPS | ₹0.57 | ₹3.99 | ₹7.46 | ₹7.08 | ₹13.38 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2025 could not be independently verified against the company's own annual report: this page shows ₹6.30 Cr while the annual report gives ₹7.68 Cr (22.0% apart).
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹39.59 Cr | ₹50.59 Cr | ₹157.92 Cr | ₹270.95 Cr | |
| ₹23.45 Cr | ₹12.25 Cr | ₹50.29 Cr | ₹93.63 Cr | |
| Stockholders' equity | ₹9.90 Cr | ₹32.45 Cr | ₹86.81 Cr | ₹152.43 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹7.22 Cr | ₹5.16 Cr | ₹10.50 Cr | ₹13.87 Cr | |
| Investing cash flow | ₹-17.41 Cr | ₹-11.27 Cr | ₹-60.17 Cr | ₹-49.74 Cr |
| ₹10.51 Cr | ₹6.17 Cr | ₹53.57 Cr | ₹37.11 Cr | |
| Capital expenditure | ₹-17.32 Cr | ₹-10.00 Cr | ₹-23.35 Cr | ₹-46.36 Cr |
| End cash position | ₹34.59 L | ₹40.85 L | ₹4.31 Cr | ₹5.55 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| Qualitek Labs Limited | ₹754.59 Cr | ₹616.8 | 51.8 | 4.95 | 8.9% | 0.61 | +77.3% | +47.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.